Reply to ‘ Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure ’

Reply to ‘Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure’ Hypertension Research 40, 900 (05 October 2017). doi:10.1038/hr.2017.59 Authors: Miki Imazu, Hiroyuki Takahama & Masafumi Kitakaze
Source: Hypertension Research - Category: Cardiology Authors: Source Type: research